Triapine

Phase 3Small molecule

Triapine is a small molecule that works as a Ribonucleotide Reductase Inhibitor.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]

Triapine is one of 13 small molecule programs targeting Metastatic Neuroendocrine Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Neuroendocrine TumorActive, not recruiting

Astrocytoma, IDH-Mutant, Grade 2Recruiting

Advanced Vaginal AdenocarcinomaActive, not recruiting

Advanced Cervical AdenocarcinomaActive, not recruiting

Uterine CancerActive, not recruiting

Metastatic Neuroendocrine TumorPhase 2

Active, not recruiting

Astrocytoma, IDH-Mutant, Grade 2Phase 1

Recruiting

Advanced Vaginal AdenocarcinomaPhase 3

Active, not recruiting

Advanced Cervical AdenocarcinomaPhase 1

Active, not recruiting

Uterine CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Uterine Cancer

#DrugCompanyPhaseTrials

Afinitor

Femara

Taxol

6 4

Gemzar

Johnson & Johnson

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

3 6

Adavosertib

AstraZeneca

Phase 2

1 7

Triapine

VVion Pharmaceuticals

Phase 3

1 8

Paraplatin

AAvyxa

Phase 2

4 9

Zanzalintinib

Merck & Co.

Phase 1

1 10

RP-6306

DDebiopharm International SA

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Metastatic Neuroendocrine Tumor

NCT05724108

Q1 2027

Phase 1Active, not recruiting

Metastatic Digestive System Neuroendocrine Neoplasm

NCT04234568

Q2 2027

Phase 1Active, not recruiting

Advanced Cervical Adenocarcinoma

NCT02595879

Phase 1Recruiting

Astrocytoma, IDH-Mutant, Grade 2

NCT06860594

Q3 2027

Phase 3Active, not recruiting

Advanced Vaginal Adenocarcinoma

NCT02466971

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Completed·CCancer Therapeutics Research Group·Phase 2·NCT00077415·31 enrolled

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00064064

A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077350·48 enrolled

Pancreatic Cancer3 trials

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00064051

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00288093·30 enrolled

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00078975·26 enrolled

Advanced Cancer2 trials

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00024323

3-AP in Treating Patients With Advanced Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00006218

Breast Cancer1 trial

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00095888·68 enrolled

Lymphoma1 trial

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00293345·30 enrolled

24 more indications

Patients With Solid Tumors1 trial

3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors

Completed·VVion Pharmaceuticals·Phase 1·NCT00004213

Hematologic Cancer1 trial

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00064090

Cancer of the Pancreas1 trial

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00085371·116 enrolled

Advanced Hematologic Malignancies1 trial

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077181·48 enrolled

Radiation Therapy1 trial

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00335998·24 enrolled

Advanced or Metastatic Solid Tumors1 trial

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00390052·24 enrolled

Gallbladder Cancer1 trial

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075504·33 enrolled

Renal Cell Carcinoma1 trial

3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00075660·19 enrolled

Adenocarcinoma1 trial

3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077545·39 enrolled

Metastatic Cancer1 trial

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00016874

Myelodysplastic Syndrome1 trial

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00077558

Primary Peritoneal Cancer1 trial

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00081276·48 enrolled

Refractory Solid Tumors1 trial

3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079014·36 enrolled

Uterine Cancer1 trial

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04494113·12 enrolled

Unresectable Solid Tumor1 trial

Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00084877·36 enrolled

Chronic Myelomonocytic Leukemia1 trial

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00381550·35 enrolled

Cervical Cancer1 trial

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00941070·26 enrolled

Prostate Cancer1 trial

3-AP in Treating Patients With Advanced Prostate Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00054015

Metastatic Digestive System Neuroendocrine Neoplasm1 trial

A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04234568·31 enrolled

Recurrent Glioblastoma IDH Wildtype1 trial

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

Recruiting·NNorthwestern University·Phase 1·NCT06410248·22 enrolled

Astrocytoma, IDH-Mutant, Grade 21 trial

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06860594·30 enrolled

Advanced Vaginal Adenocarcinoma1 trial

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02466971·450 enrolled

Advanced Cervical Adenocarcinoma1 trial

Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02595879·21 enrolled

Metastatic Neuroendocrine Tumor1 trial

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05724108·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Triapine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triapine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triapine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vion Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Ribonucleotide Reductase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVion Pharmaceuticals

Triapine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Pancreatic Cancer3 trials

Advanced Cancer2 trials

Breast Cancer1 trial

Lymphoma1 trial

Patients With Solid Tumors1 trial

Hematologic Cancer1 trial

Cancer of the Pancreas1 trial

Advanced Hematologic Malignancies1 trial

Radiation Therapy1 trial

Advanced or Metastatic Solid Tumors1 trial

Gallbladder Cancer1 trial

Renal Cell Carcinoma1 trial

Adenocarcinoma1 trial

Metastatic Cancer1 trial

Myelodysplastic Syndrome1 trial

Primary Peritoneal Cancer1 trial

Refractory Solid Tumors1 trial

Uterine Cancer1 trial

Unresectable Solid Tumor1 trial

Chronic Myelomonocytic Leukemia1 trial

Cervical Cancer1 trial

Prostate Cancer1 trial

Metastatic Digestive System Neuroendocrine Neoplasm1 trial

Recurrent Glioblastoma IDH Wildtype1 trial

Astrocytoma, IDH-Mutant, Grade 21 trial

Advanced Vaginal Adenocarcinoma1 trial

Advanced Cervical Adenocarcinoma1 trial

Metastatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News